
Browsing restrictions can be lifted for a fee.
Megaforce Company Limited engages in the provision of professional plastic components and opto-mechatronics services in Taiwan, China, Mexico, and the United States. The company engages in precise plastic injection molding, micro-precision structure mold development, electronic assembly, spray printing, liquid silicone rubber molding, design for manufacturing, tooling, and other related activities. It also offers dental electromechanical integration products, da Vinci surgical systems, medical integration products through Internet of Things, and medical machinery products, as well as medical teaching courses. In addition, the company provides surface treatment, post process, and assembly services; and engages in the development of key materials, and design of mechanical and material processes. Its products are used in advanced computer gaming, home entertainment equipment, vehicle components, medical appliances, and aerospace equipment, as well as in computer, communication, and consumer electronics products. The company was founded in 1991 and is headquartered in New Taipei City, Taiwan.
3294
英濟
-3.32%
(-0.03)
The most recent financial report for 英濟 (3294) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 3294's short-term business performance and financial health. For the latest updates on 3294's earnings releases, visit this page regularly.
According to the latest financial report, 英濟 (3294) reported an Operating Profit of 66.31M with an Operating Margin of 6.07% this period, representing a growth of 189.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 英濟 (3294) announced revenue of 1.09B, with a Year-Over-Year growth rate of -9.6%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 英濟 (3294) held Total Cash and Cash Equivalents of 802.57M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 英濟 (3294) achieved the “three margins increasing” benchmark, with a gross margin of 19.53%%, operating margin of 6.07%%, and net margin of 4.97%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 3294's profit trajectory and future growth potential.
According to the past four quarterly reports, 英濟 (3294)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.46. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
英濟 (3294)'s Free Cash Flow (FCF) for the period is 263.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 86.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.